Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $791,345.06 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 21,142 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $791,345.06. Following the completion of the transaction, the insider owned 176,883 shares in the company, valued at $6,620,730.69. The trade was a 10.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Rajeev Saggar also recently made the following trade(s):

• On Wednesday, November 5th, Rajeev Saggar sold 71,381 shares of Liquidia stock. The stock was sold at an average price of $27.00, for a total transaction of $1,927,287.00.

Liquidia Stock Performance

Shares of LQDA stock opened at $38.79 on Friday. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The company has a market cap of $3.37 billion, a PE ratio of -26.94, a P/E/G ratio of 0.68 and a beta of 0.48. The company’s fifty day simple moving average is $32.68 and its 200-day simple moving average is $25.77. Liquidia Corporation has a 52 week low of $11.26 and a 52 week high of $41.57.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. Liquidia’s quarterly revenue was up 1106.7% on a year-over-year basis. As a group, equities research analysts anticipate that Liquidia Corporation will post -1.51 EPS for the current year.

Institutional Trading of Liquidia

Several institutional investors have recently added to or reduced their stakes in LQDA. NewEdge Advisors LLC bought a new position in Liquidia during the 2nd quarter valued at $25,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Liquidia in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC bought a new position in shares of Liquidia during the third quarter worth about $34,000. Steward Partners Investment Advisory LLC grew its stake in Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after buying an additional 4,927 shares during the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on LQDA. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and set a $49.00 target price on shares of Liquidia in a research report on Friday, January 9th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Finally, Needham & Company LLC upped their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).